Recent advances in research on natural product inhibitors of SREBPs

Sterol regulatory element-binding proteins(SREBPs)are a class of cholesterol-sensitive transcription factors that play important roles in lipid metabolism.Natural product inhibitors of SREBPs have been shown to inhibit the synthesis of free fatty acids and cholesterol,promote the burning of brown fat,and relieve insulin resistance by inhibiting different links during the synthesis,cleavage,and transport of SREBPs,thereby improving obesity,diabetes,atherosclerosis,and other metabolic diseases and disorders.There are numerous Chinese herbal medicines with verified efficacy in the treatment of metabolic diseases,including Coptis chinensis Franch.and Pueraria peduncularis Grah.for diabetes,Pueraria peduncularis Grah.,Epimedium brevicornum Maxim.,and Panax ginseng C.A.Meyer for osteoporosis,and Nelumbo nucifera Gaertn.and Poria cocos(Schw.)Wolf.for obesity.Present-day research on the mechanisms underlying the activity of traditional Chinese medicine has indicated that certain chemical components of these traditional preparations can be used to treat metabolic diseases by inhibiting SREBPs.Progress in the research on natural product SREBP inhibitors is continuing apace,and the mechanisms of action of certain small molecules have become well established.In this study,we review recent progress in the research on natural small-molecule inhibitors of SREBPs,including flavonoids,saponins,triterpenoids,and alkaloids,which we hope will provide a useful reference for future research and development of drugs for the treatment of metabolic diseases.

Hypolipidemic effect of SIPI-7623,a derivative of an extract from oriental wormwood,through farnesoid X receptor antagonism

Farnesoid X receptor(FXR) is a member of the nuclear receptor superfamily of ligand-activated transcription factors.As a metabolic regulator,FXR plays key roles in bile acid and cholesterol metabolism and lipid and glucose homeostasis.Therefore,FXR is a potential drug target for several metabolic syndromes,especially those related to lipidemia disorders.In the present study,we identified small molecule SIPI-7623,a derivative of an extract from Oriental wormwood(Artemisia capillaris),and found that it specifically upregulated the expression of cholesterol-7-alpha-hydroxylase(CYP7 A1),downregulated the expression of sterol-regulatory element-binding protein 1 c(SREBP-1 c) in the liver,and inhibited the expression of ileal bile acid binding-protein(IBABP) in the ileum of rats.We found that inhibition of FXR by SIPI-7623 decreased the level of cholesterol and triglyceride.SIPI-7623 reduced the levels of cholesterol and triglyceride in in vitro Hep G2 cell models,ameliorated diet-induced atherosclerosis,and decreased the serum lipid content on rats and rabbits model of atherosclerosis in vivo.Furthermore,SIPI-7623 decreased the extent of atherosclerotic lesions.Our resutls demonstrated that antagonism of the FXR pathway can be employed as a therapeutic strategy to treat metabolic diseases such as hyperlipidemia and atherosclerosis.In conclusion,SIPI-7623 could be a promising lead compound for development of drugs to treat hyperlipidemia and atherosclerosis.